Analysts Expect Theravance Biopharma Inc (NASDAQ:TBPH) Will Announce Quarterly Sales of $13.92 Million
Equities analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to post sales of $13.92 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Theravance Biopharma’s earnings. The highest sales estimate is $16.00 million and the lowest is $12.45 million. Theravance Biopharma reported sales of $23.48 million during the same quarter last year, which indicates a negative year-over-year growth rate of 40.7%. The company is expected to announce its next quarterly earnings results on Wednesday, August 7th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $56.16 million for the current financial year, with estimates ranging from $45.78 million to $65.00 million. For the next financial year, analysts anticipate that the firm will report sales of $102.99 million, with estimates ranging from $74.18 million to $129.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.14). The company had revenue of $5.34 million during the quarter, compared to the consensus estimate of $16.45 million. Theravance Biopharma had a negative return on equity of 2,631.71% and a negative net margin of 388.61%.
Shares of NASDAQ TBPH traded up $0.32 during mid-day trading on Friday, reaching $17.34. The company had a trading volume of 192,336 shares, compared to its average volume of 260,218. The stock’s 50-day moving average price is $16.66. The firm has a market cap of $973.47 million, a PE ratio of -4.35 and a beta of 1.76. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $35.48.
In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $20.46, for a total transaction of $81,840.00. Following the transaction, the director now directly owns 30,244 shares in the company, valued at approximately $618,792.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the business. DekaBank Deutsche Girozentrale boosted its holdings in Theravance Biopharma by 21.9% in the first quarter. DekaBank Deutsche Girozentrale now owns 11,700 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 2,100 shares in the last quarter. Fosun International Ltd acquired a new position in Theravance Biopharma in the first quarter valued at approximately $2,386,000. NJ State Employees Deferred Compensation Plan boosted its holdings in Theravance Biopharma by 6.9% in the first quarter. NJ State Employees Deferred Compensation Plan now owns 31,142 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 2,000 shares in the last quarter. SG Americas Securities LLC acquired a new position in Theravance Biopharma in the first quarter valued at approximately $156,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in Theravance Biopharma by 882.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after purchasing an additional 8,951 shares in the last quarter. Institutional investors own 84.75% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Read More: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.